| Name | Title | Contact Details |
|---|
Kedalion Therapeutics is a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, CA. Kedalions AcuStream technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable efficacy with an 80% reduction in dose compared to standard drops, and a significantly improved side effect profile along with patient comfort and convenience following self-administration.
With nearly 8,500 employees, more than 1,500 medical staff members, and 837 licensed beds, Bronson Healthcare is the largest employer and leading healthcare system in southwest Michigan. It offers a full range of services from primary care to critical care across more than 100 locations. Key member organizations include: Bronson Methodist Hospital, Bronson Battle Creek, Bronson LakeView Hospital, Bronson South Haven Hospital, Bronson Medical Group, Bronson at Home, Bronson Commons, Bronson Athletic Club, Bronson Wellness Center and the Bronson Health Foundation.
Serving Southeastern Wisconsin since 1974, Home Care Medical, Inc. provides home infusion, enteral nutrition and hospice care; rehab technology; respiratory care; home medical equipment and supplies; and bracing and compression garments. In addition to the Corporate Headquarters located at 5665 South Westridge Drive in New Berlin, Wisconsin, Home Care Medical, Inc. has three retail store locations at 4818 South 76th Street in Milwaukee, Wisconsin; 2922 South Business Drive in Sheboygan, Wisconsin; and 1709 South 18th Avenue in West Bend, Wisconsin. Home Care Medical, Inc. is the WAMES (Wisconsin Association of Medical Equipment Services) HME Provider of the Year award recipient in 2013 and 2012. Accredited by the Joint Commission and an active member of WAMES, the MedGroup and AAHomecare, Home Care Medical’s mission is to enhance the lives of those we serve.
Visiting Nurse and Community Health is a Arlington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings. All of FibroGen`s therapeutic candidates have been internally developed based on FibroGen`s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).